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1 Introduction 
1.1 Staphylococcus aureus – a major global human pathogen 
The bacterium Staphylococcus aureus (S. aureus) is part of the family of Gram-
positive Staphylococcaceae. It most commonly occurs as a commensal 
bacterium present on the human skin and the mucosae (epithelia), here 
primarily in the anterior nares [1, 2]. Nevertheless, under certain conditions, 
such as a host–bacterium disbalance [3], the commonly asymptomatic S. 
aureus carriage can lead to a wide spectrum of diseases [2,4]. 
 
1.1.1 History 
Already in 1874 Theodor Billroth described micrococci in pus [5]. But it was only 
in 1882 that the Scottish surgeon Alexander Ogston first proposed the name 
Staphylococcus [6]. In 1880 [19], Ogston recovered bacteria in pus from 
abscesses and observed grapelike clusters under the microscope. 
Henceforward, the name Staphylococcus (from “staphyle”, Greek for “bunch of 
grapes” and “kokkos”, Greek for “berry”) [7, 6] became the accepted designation 
for this special kind of micrococci that had now been identified as the major 
cause of pus. 
Two years later, in 1884, Anton J. Rosenbach devided the genus 
Staphylococcus into two species [8]. According to the pigmented appearance of 
their colonies, he called them S. aureus (“aureum”, Latin for “gold”) and 
Staphylococcus albus (“albus”, Latin for “white”): the latter is referred to today 
as Staphylococcus epidermidis. These pigments were later classified as 
carotenoids, and in S. aureus the pertinent biosynthetic pathway has recently 
been identified [9]. 
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1.1.2 Epidemiology 
S. aureus is capable of colonizing multiple sites of the human skin and 
mucosae, but the anterior nares appear to be its primary ecological niche and 
reservoir [4, 1]. Extra-nasal sites that typically harbor the organism include the 
hands, perineum, pharynx and less frequently other carriage sites including the 
gastrointestinal tract, vagina, axillae [4, 10]. 
This colonization may act as an endogenous source of subsequent bacteremia 
and other infections [11]. For this reason, that is to detect variations in the risk 
of acquiring S. aureus-related infections, as well as for statistical reasons, the 
distinction in carriage types is useful. For several decades longitudinal studies 
of healthy individuals have shown three patterns of S. aureus carriage: 
noncarriage (~50% of individuals), intermittent carriage (~30% of individuals) 
and persistent carriage (~20% of individuals) of the same or different strains [4, 
1,12, 13, 14, 15]. However, in 2009, van Belkum et al. presented a study in 
which they suggested a paradigm shift to be required. Van Belkum et al. 
propose that there are only two human types of nasal S. aureus carriers: 
persistent carriers and others [16]. This is based on findings that show that 
intermittent carriers and noncarriers share similar S. aureus nasal elimination 
kinetics and antistaphylococcal antibody profiles [16] and a low risk of infection 
as has been described in the literature earlier [15]. 
In general, a multifactorial genesis underlies S. aureus nasal carriage and, as a 
result, prevalence of S. aureus nasal carriage varies depending on an 
interaction of host factors (like age, gender, presence of chronic diseases such 
as HIV or Diabetes mellitus), environmental factors (like hospitalization, 
colonized household members) and bacterial virulence factors (like surface-
associated proteins or secreted toxins) [4]. 
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1.1.3 Bacteriology 
In order to take account of recent results of molecular phylogenetic 
classification, the genus Staphylococcus, while formerly being part of the family 
Micrococcaceae, was proposed for reclassification into the family the 
Staphylococcaceae [17]. 
 
The complete lineage is:  
Cellular organisms; Domain: Bacteria; Phylum: Firmicutes; Class: Bacilli; Order: 
Bacillales; Family: Staphylococcaceae; Genus: Staphylococcus [18]. 
 
The genus Staphylococcus consists of more than 35 species [69], of which S. 
aureus is the most virulent and in consequence also the most clinically relevant 
species [20]. 
S. aureus is a Gram-positive cocci and presents itself in clusters [2] with 
diameters of 0.5 – 1.5 μm [21]. Colonies of S. aureus can have β-hemolysis due 
to the production of the hemolysins α-toxin, β-toxin, γ-toxin, and δ-toxin. 
Staphylococci can grow in a wide pH range (4.8 – 9.4), are able to resist drying, 
and can survive at temperature extremes as high as 60°C for up to 30 min [22]. 
In addition, S. aureus is capable to grow in a high-salt medium due to the 
production of osmoprotectants [23], and can tolerate 7.5% –10% sodium chlorid 
[22]. S. aureus is facultative anaerobic, non-motile, non-spore forming and 
possesses a number of virulence factors (e.g., coagulase, clumping factor) 
which play a role in the differentiation to other less virulent Staphylococcus 
spp.[5]. 
 
1.1.4 Molecular characteristics 
1.1.4.1 Genome structure 
The first sequenced S. Aureus genomes were those of the two methicillin-
resistant S. aureus (MRSA) strains N315 and Mu50 by Hiramatsu’s group in 
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2001 [24], followed by additional strains over the next ten years (among others 
MW2 [25], MRSA252 and MSSA476 [26], COL [27], USA300-IPR3737 [28], 
USA300-HOU-MR [29], NCTC8325 [30], ET3-1 [31], JH1 and JH9 [32], 
Newman [33], JKD6008 [34], and T0131 [35]).  
Currently, there are about 24 annotated whole genome sequences of S. aureus 
in the public domain (www.ebi.ac.uk/genomes/bacteria.html). The number of 
sequenced genomes is growing at a fast rate as whole genome sequencing is 
becoming faster and less expensive. 
All staphylococcal genomes consist of a circular chromosome, approximately 
2.8 Mbp in size with a relatively low GC-content of 33% and several plasmids 
[5]. Comparative analysis revealed that most regions of the staphylococcal 
genome are well conserved, whereas several large parts of the genome display 
high variability [33].  
 
Core genome and MGE 
S. aureus genome is typically composed of a basic structure, which is a 
syntenous conserved core genome with all the genes vital to cell survival, and 
of a collection of mobile genetic elements (MGEs) that constitute about 25% of 
the whole genome [36, 37, 38]. MGEs are fragments of DNA integrated 
throughout the genome and may be classified as insertion sequences, 
transposons, phages, plasmids, pathogenicity islands, and chromosome 
cassettes. MGEs carry a variety of staphylococcal resistance and virulence 
genes: plasmids (e.g. etb, sed), phages (e.g. sea) or pathogenicity islands (e.g. 
tst, sec, seg, sei) [62,24]. By means of these MGEs, DNA transfer occurs 
horizontally between species and genera [36, 37] and vertically to daughter 
cells [39]. 
It is known that within the core genome there are core variable (CV) regions. 
These regions contain genes with a higher nucleoside substitution rate than 
core genes and often exhibit variations associated with lineage [36]. 
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1.1.4.2 Virulence factors 
S. aureus expresses a wide array of virulence factors that facilitate attachment, 
colonization, cell–cell interactions, immune evasion, and tissue damage [26]. 
They act in concerted manner during the invasion processof infection [40]. 
Depending on whether the virulence factors remain associated with the cell 
surface or whether they are exported into the extracellular milieu, two groups 
(surface-associated virulence factors and extracellular virulence factors) can be 
distinguished [41]. Numerous of theS. aureus’ putative and proven virulence 
factors are encoded in MGEs [37]. 
 
 
1.1.4.2.1 Surface-associated virulence factors 
Surface-associated virulence factors consists of structural components of the 
wall (e.g., wall teichoic acid, lipoteichoic acid, lipoprotein, peptidoglycan), 
surface exposed proteins (e.g., Protein A, fibronectin-binding proteins, 
fibrinogen-binding proteins) and extracellular polysaccharides (e.g., capsular 
polysaccharides (clinically relevant are serotypes 1,2,5 and 8) and 
polysaccharide intercellular adhesins (PIA, also referred to as poly-N-acetyl 
glucosamine/PNAG)) [42]. 
 
Protein A – an important virulence factor 
Almost all isolates carry staphylococcal protein A (SpA) [40], a protein of 42 kDa 
encoded in the CV regions of the core genome [36] and consisting of several 
regions with distinct functions [43]. The N-terminal part is comprised of the 
signal sequence (S region) followed by four or five highly homologous 
immunoglobulin G (IgG)-binding domains in tandem (the E, D, A, B, and C 
regions) and is displayed on the cell surface [43,44, 45]. The C-terminal region, 
also referred to as X region, is anchored to the bacterial cell wall and “is divided 
into two domains: (i) the repeat region XR, consisting of variable repeats with 
mostly octapeptide structures, which are used for spa typing, and (ii) the XC 
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region, consisting of a conserved sequence, which confers anchoring to the cell 
wall via an LPXTG-binding motif.” [44] 
 
 
Figure1: spa region (from [44]) 
 
A well-studied function of SpA is its interaction with human IgG. SpA has the 
ability to bind with the Fc part of the immunoglobulins, so that neutrophils are 
unable to recognize the IgG molecules coating the cell surface. Thereby the 
host immune system is compromised through the protection of opsonization and 
phagocytosis of the bacterium [44, 46]. 
In addition, SpA can also interact with other host structures including the von 
Willebrand factor and the receptor gC1qR/p33 on platelets [47, 48, 49] and it 
plays a role in biofilm formation [50]. 
 
1.1.4.2.2 Extracellular virulence factors 
The extracellular virulence factors include toxins, namely exfoliative toxins (eta, 
etb, etd), staphylococcal enterotoxins (sea, seb, sec, sed, see, seg, seh, sei, 
sej), toxic shock syndrome toxin 1 (TSST-1), heamolytic/cytolytic toxins (α-, β-, 
γ-, δ-toxin and PVL) as well as epidermal cell differentiation inhibitor exotoxins 
(Edin-A, Edin-B, Edin-C) and they also include exoenzymes (protease, 
thermonuclease (thermostable nuclease, NUC)).  
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Panton-Valentine leukocidin – its role in the pathogenesis and course of 
disease  
Panton-Valentine leukocidin (PVL) is a poreforming cytotoxin that is produced 
by about 2% of methicillin-susceptible S. aureus n Europe [40] and belongs to 
the family of synergohymenotropic toxins [51]. This toxin consists of two 
separate synergistic protein subunits (referred to as LukS-PVL and LukF-PVL) 
encoded by two co-transcribed genes, lukS-PV and lukF-PV, which are carried 
on a temperate bacteriophage integrated in the S. aureus chromosome [52]. 
These toxins damage membranes of mononuclear and polymorphonuclear cells 
and cause cell death by necrosis or apoptosis [51]. It is to be noted that 
community-associated methicillin-resistant S. aureus (CA-MRSA) strains are 
highly likely to be PVL positive [53] and there is some evidence indicating that 
PVL may contribute to the virulence of these strains [54] and may even lead to 
higher mortality among immunocompetent individuals through necrotizing 
pneumonia [55]. Characteristically, these CA-MRSA strains tend to carry 
staphylococcal cassette chromosome type IV and less frequently V [28, 56]. 
Another member of the same family of toxins – the synergohymenotropic toxins 
– is y-hemolysin encoded by hlg genes. 
 
1.1.4.3 Production control of virulence factors 
The expression of S. aureus’ wide array of virulence factors is influenced in a 
complex way by the accessory gene regulator (agr) locus and the 
staphylococcal accessory regulator (sarA) locus [57, 58]. 
Agr encodes a two-component signaling pathway whose activating ligand is a 
self-coded bacterial-density-sensing peptide (auto-inducing peptide [AIP]) 
binding to AgrC [59]. On the basis of a polymorphism of its AIPs, four major 
groups of agr (agr I to IV) in S. aureus strains can be distinguished [60]. The agr 
response is an increased expression of the regulatory RNA (RNAIII) which 
regulates the production of S. aureus virulence factors transcriptionally and 
posttranscriptionally. According to Jon S. Blevins et al., mutation in agr leads to 
an increased production of surface proteins, decreased production of 
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exoproteins, and reduced virulence [41]. However, they also point out that it has 
been reported that agr may influence regulatory strains differently [41]. 
SarA locus is the other important regulatory locus that also modulates the 
virulence production. Its protein (SarA) binds within promoter regions of genes 
encoding cell surface proteins (spa, encoding protein A), genes encoding 
exoproteins (hla, encoding alpha-hemolysin), and also agr [61]. SarA binding to 
agr promoter regions increases RNAIII transcription and therefore indirectly 
modulates virulence factor production but it has also been shown that SarA 
controls regulation of a number of virulence factors directly, in an agr-
independent manner [62]. 
Expression of SarA is seen to promote biofilm formation whereas expression of 
agr is seen to limit biofilm formation [63]. Interestingly, Karen E. Beenken et al. 
demonstrated that sarA is epistatic to agr in regard to biofilm formation [63]. 
 
1.1.4.4 Staphylococcal cassette chromosome  
Staphylococcal cassette chromosome (SCC) is a MGE that is typically 
associated with methicillin resistance as many carry the mecA (SCCmec).The 
mecA or mecC encodes for a mutated penicillin binding protein (PBP) which 
confers resistance to almost all beta-lactam antimicrobial drugs by reducing 
affinity. SSCmec comprises the mec complex, with the regulatory genes and 
associated insertion sequences,and the ccr complex, which encodes for 
recombinases allowing integration and excision of SCCmec [64]. Additionally, 
the SCCmec elements may also contain other MGEs, e.g., plasmids or 
transposons which sometimes carry other resistance genes [65]. The 
acquisition/presence of the mecA gene results in methicillin resistance and 
resistance to all other β-lactam antibiotics by the production/output of its gene 
product PBP2a (aka PBP2'); PBP2a is an additional penicillin-binding protein, 
which has reduced affinity for β-lactam antibiotics [66, 67]. Normally, β-lactam 
antibiotics bind to PBPs in the cell wall, thereby stopping the biosynthesis of the 
cell wall and resulting in the death of the bacterium. Since PBP2a does not 
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allow this binding to occur, the biosynthesis of the cell wall is not disrupted and 
the bacterium lives on.  
The origin of the mecA gene has not yet been defined. However, there is 
evidence that coagulase-negative staphylococci may act as its potential 
reservoir as it has been shown that horizontal transfer of SCCmec between 
staphylococci is likely to be possible [65]. 
By now, eleven major types (I to XI) of SCCmec have been described for S. 
aureus based on the combinations of the classes of the mec gene complex and 
the types of the ccr gene complex [68]. 
SCCmec types I, II or III are larger in size (34–67 kb) and are usually 
associated with hospital-acquired MRSA infections. The two smallest SCCmec 
types, either type IV (24 kb) or less frequently, SCCmec V, are associated with 
community-associated MRSA (CA-MRSA) [56]. 
 
1.1.5 Diagnostic 
Phenotypic and genotypic methods 
There are numerous methods to identify staphylococcus and staphylococcus 
subspecies, all varying in their sensitivity, specificity, standardization, 
reproducibility, time expenditures, costs and technical requirements. Classic 
phenotypic diagnostic methods are based on colony morphology, Gram 
straining, colony growth on sheep blood agar, catalase testing, rabbit plasma 
coagulase testing, clumping factor testing, a latex agglutination test as well as 
tests for biochemical characteristics such as enzymes. 
Molecular species identification includes sequencing of universal target 
sequences (e.g., 16S RNA gene, rpoB [148] or the amplification of specific 
genes (e.g., thermonuclease (nuc), fibrinogenreceptor (clfA), coagulase (coa)) 
and genotyping (PFGE, spa typing, MLST) [69]. 
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Spa typing 
Spa typing is a sequence-based S. aureus-typing method which is fast, highly 
discriminatory, and reproducible [70]. It is based on single locus DNA-
sequencing of the hyper-variable XR-region of the Staphylococcusprotein A 
gene (spa). This XR-region consists of base pair (~ 24) repeats in different 
numbers (2 – 16). With the help of this polymorphism different S. aureus strains 
can be distinguished and named unambiguously as every repeat is given an 
alpha-numerical code and the spa type results from the kind and order of the 
specific repeats [71, 72]. This became possible with the development of 
databases that collate and harmonize data from different geographic areas such 
as the Ridom StaphType software (Ridom GmbH,Germany) [73]. The RIDOM 
(Ribosomal Differentiation of Microorganisms) web server is based on quality-
controlled sequence entries and provides a sequence database that is 
comprehensive and validated [74]. It has been shown that the spa region is 
useful for short-term evolutionary events as well as for long-term phylogeny and 
it helps to determine clonal relatedness among different strains [75]. BURP–
Algorithm, an algorithm that is based upon repeat pattern allows to form clusters 
of related spa types [76]. 
 
MLST 
Multilocus sequence typing (MLST) is another “nucleotide sequence based 
approach for the unambiguous characterization of isolates of bacteria and other 
organisms via the internet” [77]. MLST is on the basis of the sequences of ~ 
450-bp internal fragments of seven conserved housekeeping genes [78]. 
Initially, MLST had been developed 1998 by Martin Maiden, Dominique 
Caugant, Ian Feavers, Mark Achtman and Brian Spratt for Neisseria 
meningitides [78]. For S. aureus, the use of MLST has been described by Mark 
Enright in 2000 [100]. 
For each unique sequence of the fragments of the seven housekeeping genes a 
specific allele is assigned. A sequence type is then defined by allelic profile 
[100]. 
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The following seven housekeeping genes are used for theS. aureus MLST 
scheme: arcC (carbamate kinase), aroE (shikimate dehydrogenase), glpF 
(glycerol kinase), gmk (guanylate kinase), pta (phosphate acetyltransferase), tpi 
(triosephosphate isomerase) and yqiL (acetyle coenzyme A acetyltransferase) 
[100]. These genes are located throughout the whole genome. 
MLST data is freely available to anyone via the internet (http://saureus.mlst.net/) 
as is the eBURST software (http://eburst.mlst.net/) which allows to cluster clonal 
complexes (CC) of the sequence types (ST) of isolates (corresponding to 
groups of closely related strains) by grouping the STs with STs of the whole 
MLST database. The CCs predict “the founding genotype of each group, and 
displays the patterns of recent evolutionary descent of all other strains in the 
group from the founder.” [130, 131].  
High concordance of results between spa typing, MLST and other widely-used 
typing methods as PFGE and microarray has been shown [79]. There are even 
some studies that have showed that spa typing sometimes offers greater 
resolution than MLST [73]. 
 
1.1.6 Clinical features 
S. aureus mostly asymptomatically colonizes the skin, but provided the needed 
conditions, its pathogenic potential is versatile in causing infections of different 
degrees of severity. Infections may range from minor skin infections to life 
threatening invasive diseases and to toxin mediated disease (such as food 
poisoning, staphylococcal scalded skin syndrome, and toxic shock syndrome). 
 
1.1.7 Treatment 
The treatment of choice for S. aureus infection is the use of antibiotics topically 
or systemically and is sometimes accompanied with disinfectants. 
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1.1.7.1 Antibiotics and their limits - the emerge of multi resistance 
Over the past decades multidrug resistant (MDR) S. aureus strains have 
emerged and they are a major concern worldwide because of the diminishing 
therapeutic efficacy of known antimicrobial agents.  
Even though the mortality rate of S. aureus bacteremia has been reduced, from 
80% in times before the introduction of penicillin in the early 1940s to 20–40% 
nowadays, it remains a threat [80]. Already in 1942 penicillin-resistant strains 
were found first in hospitals and then in the community and in the 1960s about 
80% of all S. aureus isolates showed a resistance to penicillin in Denmark [80, 
149]. This resistance is due to β-lactamase (penicillinase), an enzyme that 
hydrolyzes the β-lactam ring resulting in its inactivation. High occurrence of β-
lactamase (> 90%) is now common in the United States [80]. 
Additionally, with the introduction of the penicillinase-stable antimicrobial drug 
methicillin in 1961 resistance to this agent was reported shortly after. Methicillin 
resistant S. aureus (MRSA) was first detected in a British hospital and spread 
quickly in Europe, Australia, and the United States, while not restricting itself to 
hospital settings and causing community-acquired MRSA infection outbreaks 
[80]. Depending on the countries’ infection control regulations, MRSA rates 
increased (USA) [1], stayed steady or dropped (Netherlands) over the years. In 
Africa the first MRSA cases were described in the literature only in 1988 by 
Peddie et al. [81].  
Often resistance to various other antibiotics is associated with resistance to 
methicillin (so called MDR). The report of vancomycin-resistant strains in the 
USA in 2002 [82] has been the cause of new concern as the glycopeptide 
antibiotic vancomycin has been regarded as the drug of "last resort" for a long 
time. This resistance is developed by the acquisition of the vanA gene through 
transfer from an Enterococcus faecalis [80]. 
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1.1.7.2 Mupirocin for decolonization 
Several studies showed that an effective way of reducing staphylococcal 
infections is to eliminate the nasal carriage of S. aureus [16]. Interestingly, this 
S. aureus eradication may only last for weeks or months before a recolonization 
of the anterior nares occurs [16]. For topical use a two percent mupirocin 
calcium ointment is available that successfully eliminates S. aureus skin 
colonization. Generally, mupirocin is used to decolonize nasal MRSA carriers 
and it is applied to the nose twice daily for five days. However, concerns 
regarding resistance exist and resistance has occurred especially when used 
unconfined. 
 
1.1.8 Central Africa, Gabon and Lambaréné 
The region of Central Africa includes Burundi the Central African Republic, 
Chad, the Democratic Republic of the Congo, Rwanda, Angola, Cameroon, the 
Central African Republic, Chad, the Republic of the Congo, the Democratic 
Republic of the Congo, Equatorial Guinea, São Tomé and Príncipe, and Gabon.  
Gabon is located in the west of central Africa. It is equatorial and extends over 
an area of almost 268.000 km² [84]. Important Gabonese towns are Libreville, 
Franceville, Port-Gentil, Oyem, and Lambaréné, among others. 
 
1.2 Objective and scope of this dissertation 
S. aureus isolates have been analyzed in numerous studies but most of them 
examined S. aureus isolates from developed countries. In fact, the incidence of 
severe S. aureus infections causing mortality is much higher in developing 
countries than in developed countries [87,88]. Limited information exists of S. 
aureus from Africa, especially its carrier rate, virulence patterns, molecular 
diversity, and epidemiology. For obvious reasons, insight into the population 
structure of S. aureus is central to assess the pathogenicity/virulence of 
different strains of S. aureus. Hence this dissertation is an essential contribution 
to epidemiological surveillance and provides a much needed contribution to the 
1 Introduction 
14 
knowledge on which to base public health decisions to prevent staphylococcol 
related diseases in the Lambaréné area, and, more generally, in Gabon and 
Central Africa.  
The main objective of this dissertation is to obtain a better understanding of the 
population structure of S. aureus in the study region. In order to do so, this 
dissertation documents the population structure of S. aureus isolated from the 
nose, the axilla and the groin of 500 study participants living in the city of 
Lambaréné or in villages in its surrounding rural environment (the “Lambaréné 
area”).The other important objective is to assess the S. aureus population 
structure in the Lambaréné area by putting it into comparison with the 
population structure found in other geographical regions. 
 
1.3 Previous publication 
The study population and analysis of this dissertation is closely related to that 
described in the following article: Ateba Ngoa U, Schaumburg F, Adegnika AA, 
Kösters K, Möller T, Gaus E, Fernandes JF, Alabi A, Issifou S, Becker K, 
Grobusch MP, Kremsner PG and Lell B (2012) Epidemiology and population 
structure of Staphylococcus aureus in various population groups from a rural 
and semi urban area in Gabon, Central Africa. Acta Trop 124: 42-47 [106]. 
For this reason some of the results included in this dissertation (results 3.1 to 
3.3, part of results of 3.4.4, and most of the results in 3.5) have already been 
published in this article. 
These results are included here in order to complement the original results of 
this dissertation and to thereby give a more complete overview of the 
characteristics of S. aureus in the study region. 
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2 Material and methods 
2.1 Study design and study site 
This cross-sectional, descriptive study was conducted in Lambaréné, Gabon 
and the rural environment of Lambaréné from February 2009 to July 2009. The 
study design and study site has been briefly described previously by Ateba-
Ngoa et al. [106]. 
Gabon is covered to 80% with rain forest and has a coastline of over 800 km 
with the Atlantic Ocean (Gulf of Guinea) in the west. It borders on Equatorial 
Guinea in the northwest, Cameroon in the north and on the Republic of the 
Congo in the east and south. Gabon`s population is estimated at about 1.5 
million with approximately 674 thousand living in Libreville, its capital and 
largest city situated in the northwest of the country [83].  
Gabon’s wealth of natural resources (oil, wood, and mineral reserves such as 
gold, uran, mangan, and ferum) contributes to its status as one of the wealthiest 
Sub-Saharan countries of Africa. Still, the majority of the population lives in 
poverty [84]. 
In Gabon, the climate is tropical with a high humidity of about 84% as a yearly 
average. The temperature stays high throughout the year at about 26°C with 
small seasonal variations. Seasonal variations in rainfall are higher with up to 
490 mm per month in the rainy seasons and 7 mm per month in the dry 
seasons in Libreville, making for a total annual precipitation of about 2,850 mm 
[85]. 
The country is divided into nine provinces. Lambaréné is, with about 35,000 
inhabitants, the capital of the province Moyen-Ogooué. It is located in the rain 
forest on the banks of the river Ogooué, which is ca. 1.200 km long and 
Gabon's largest river.  
In Lambaréné in 2008 and 2009, three hospitals were responsible for the 
primary health care of the population and in the surrounding area basic medical 
care was carried out by dispensaries. One of the hospitals is the Hôpital Albert–
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Schweitzer (HAS) which exists since 1913 and is a private institution, 
subsidized by the Gabonese state and the Albert Schweitzer Foundation. The 
following departments are present in HAS: surgery 1, surgery 2 (infectious 
cases), internal medicine, maternity ward, and pediatrics, including all together 
around 180 beds, as well as an outpatient clinic, an emergency ward, and a 
dental clinic. Most of the times, six to eight doctors are employed. In 2008, 
approximately 24,000 consultations took place, the emergency ward saw about 
3,100 cases and around 6,000 patients were hospitalised, with the most 
frequent reason for admission being cited as infectious diseases (~1,500 cases) 
[86]. 
The Hôpital Régional de Lambaréné provides departements of internal 
medicine, surgery, gynecology, and pediatrics, as well as an emergency ward 
and a dental clinic.  
Participants of this study were recruited in Lambaréné, its hospitals, and 
surrounding villages as far away as 40 km. Initial culture, species identification 
and antimicrobial susceptibility testing were all done in the Microbiology 
Laboratory of the Centre de Recherches Médicales de Lambaréné (CERMEL), 
Gabon. Further molecular characterization was carried out at the Institute of 
Medical Microbiology, University of Münster (Germany). 
 
2.2 Study population 
The study population comprised three major groups: one group was formed by 
inpatients of the Hôpital Albert–Schweitzer (HAS) and included patients from 
conservative wards (medical ward, pediatric ward), wards with invasive 
interventions (surgical ward, operation theatre) and wards with mixed 
specialties (maternity ward, emergency room). The second group consisted of 
health care workers from HAS and the Hôpital Régional de Lambaréné and 
included doctors, nurses, and cleaning staff. Inhabitants of Lambaréné (semi-
urban area) and the surrounding villages (rural area) formed the third group and 
included individual from all social classes. All participants were asymptomatic 
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for S. aureus-related diseases. It is nearly the same study population as 
published previously by Ateba-Ngoa et al. [106]. 
 
2.3 Recruitment 
The recruitment procedures of inpatients was done during regular morning 
rounds in the different wards as described previously [106]. The inpatients were 
chosen randomly, regardless of the length of their hospitalization with the 
intention to obtain similar numbers of participants from each ward. To recruit the 
health care workers, a list of all hospital staff was supplied by the hospital 
administration, so that everyone on the list could be visited by the study team 
during the morning rounds or on appointment. By the end of recruitment most of 
the hospital staff was enrolled in the study. Recruitment of the third group of 
inhabitants of Lambaréné and the surrounding villages was performed randomly 
by going from house to house in different districts and villages. As intended, we 
included about the same number of persons from the rural area and the semi-
urban area. All persons present at the time of the visits were invited to 
participate in the study. Exclusion criteria were obvious S. aureus–related 
diseases and non-acceptance of the informed consent form. Recruitment of the 
study population was stopped after an enrollment of 500 participants. 
 
2.4 Bacterial isolates – phenotypic characterization 
The phenotypic characterisation was done as previously described [106]. 
Bacterial isolates were obtained from several body sites, namely the anterior 
nares, the axilla, and the groin. These body sites were swabbed with sterile 
cotton swabs. The swabs were then stored in Amies medium (BBL 
CultureSwab, Becton Dickinson, Belgium) and cultured on 5% sheep blood agar 
plates (Columbia Agar, BioMérieux) at 362°C for 48 hours.S. aureus 
identification was based on colony morphology, Gram-straining, colony growth 
on colistin and naladixic acid Agar (BioMérieux), catalase testing, rabbit plasma 
coagulase test (BD, Belgium), and Staphaurex Plus latex agglutination test 
(Remel, Germany). Species antibiotic susceptibility testing was performed by 
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the standardized agar disc diffusion method according to National Clinical and 
Laboratory Standard Institute (NCCLS) [89] using Müller-Hinton agar and the 
following panel of antibiotic discs: penicillin, cefoxitin, erythromycin, 
clindamycin, cotrimoxazole, and chloramphenicol. 
Cefoxitin was used to screen for resistance to methicillin. Additionally, a 
penicillin binding protein latex test (PBP2a latex test, Oxoid, Germany) was 
performed on all cefoxitin resistant isolate to confirm methicillin resistance. 
Subsequently, the samples were stored at -80 °C in Cryotubes until shipment to 
the Institute of Medical Microbiology, University of Münster (Germany) for 
molecular characterization. 
Strains resistant to methicillin were further tested for a susceptibility to 
antibiotics including rifampicin, mupirocin, linezolid, gentamicin, levofloxacine, 
tobramycin, vancomycin, teicoplanin, fosfomycin, fusidic acid, tigecyclin, and 
nitrofurantoin, using a Vitek 2 automated system (BioMérieux, Marc l’Etoile, 
France). 
 
2.5 Molecular characterization 
Molecular characterization was performed as described previously [106]. Briefly, 
confirmation of S. aureus species was performed by detection of the 
thermonuclease (nuc) genes of S. aureus as described by Brakstad et al. [90]. 
The identification of one nuc-negative isolate was based on 16S RNA gene 
sequencing and a subsequent query of the sequences in GenBank BLAST 
database (http://blast.ncbi.nlm.nih.gov/Blast.cgi) [91]. 
Determination of methicillin-resistance was performed by the detecting the 
presence of mecA gene [92]. 
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2.5.1 SCCmec type 
SCCmec type was determined via a multiplex PCR approach [93]. 
 
2.5.2 Agr subtype 
To determine the agr type (agr I – IV) of our S. aureus isolates a multiplex PCR 
was conducted as described previously by Lina et al. [94] with a slightly 
modified pan-agr-primer (agr1-4Sa-1) as published one year later by von Eiff et 
al. [95] (5_-ATGCACATGGTGCWCATGC-3_). 
 
2.5.3 Virulence factors 
The presence of lukF-PV and lukS-PV encoding the PVL toxin was performed 
by polymerase chain reaction, as described by Lina et al. [96]. 
In addition, genes for virulence factors were detected as described previously 
[95, 97, 98, 99]. These genes include the genes for the toxic shock syndrome 
toxin (tst), for enterotoxins (sea, seb, sec, sed, see, seg, seh, sei, sej), 
exfoliative toxins (eta, etb, etd), for epidermal cell differentiation inhibitor (edin-
A, edin-B, edin-C), gamma-hemolysin (hlg) and capsular polysaccharide type 5 
and 8. 
 
2.6 Genotyping 
Genotyping procedure were described previously [106]. 
2.6.1 Spa typing und Cluster formation (BURP algorithm) 
Spa typing was performed for all isolates as published [79] using the Ridom 
StaphType software (Ridom GmbH, Germany). The oligonucleotides used for 
amplification correspond to the 5' end (1113F, 5'-
TGTAAAACGACGGCCAGTTAAAGACGATCCTTCGGTGAGC) and the 3' end 
(1514R, 5'-CAGGAAACAGCTATGACCCAGCAGTAGTGCCGTTTGCTT). PCR 
conditions were as follows: initial denaturation (95°C for 1 min), amplification 
(35 cycles of 95°C for 60 s, 60°C for 60 s and 72°C for 60 s) and final extension 
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(72°C for 5 min). DNA sequences were obtained with an ABI Prism Sequencer 
(Applied Biosystems) and analyzed with the StaphType software (Ridom 
GmbH, Germany).  
BURP (Based Upon Repeat Pattern) – a grouping algorithm implemented by 
the StaphType software – was used to cluster (spa-CC) related spa types as 
described by Mellmann et al. [76]. The two user-defined parameters (x and y) 
as default parameters were preset as recommended: exclusion of spa types 
that are shorter than five repeats (x = 5) and the maximum of four costs (y = 4) 
for clustering spa types into the same group [76]. 
 
2.6.2 Multilocus sequence typing 
For one isolate of each spa type MLST sequence types (ST) were determined 
as described by Enright et al. [100]. MLST clonal complexes were assigned to 
each ST running eBURST on the whole MLST database hosted by Imperial 
College London with a stringent group definition of at least 6/7 shared alleles 
(http://www.mlst.net) [77]. 
The seven genes included in the S. aureus MLST scheme are named arcC, 
aroE, glpF, gmk, pta, tpi, and yqiL. 
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Table 1: Sequences of primers used in the PCR (from [100]) 
 
We used an alternative primer pair for the amplification of aroE of the isolate 
with spa type t6331 (ST1822) as proposed by others [101]:  
aroE745-up, TTATCACCGTCGATGCATAGTGCA; 
aroE255-down, CGGAGTAGTATTTATCACAATATC. 
 
2.7 Treatment and control 
Participants who were colonized with MRSA were provided with Bactroban 
ointment, a Mupirocin containing ointment. Successful eradication of MRSA was 
controlled by repeated swabs and cultures after ten days of treatment. 
 
2.8 Statistics 
Statistical analysis was conducted by SPSS 16.0 and “R” software as well as by 
using the Windows Excel (XP-version) computer program. Pearson’s chi-square 
test was used to compare proportions. The significance level was set at p below 
0.05. Odds ratios for potential risk factors of carriage were calculated by logistic 
regression.  
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2.9 Ethics 
Ethical approval was obtained by the local ethics committee of Lambaréné 
(Comité d’Ethique Régional Indépendent de Lambaréné, CERIL). Before 
recruitment, and after clarification that participation was voluntary, all 
participants of the study signed a written informed consent form. 
The Deutsche Forschungsgemeinschaft (DFG, El 247/8-1) supported this study. 
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3 Results 
3.1 Study population 
The study population consisted of 500 participants divided into three major 
groups: inpatients (n = 198), health care workers (n = 97), and the general 
public (n = 205). In total 283 (57%) females and 217 (43%) males participated. 
At the time of enrollment, the youngest participant was one month old and the 
oldest had a verified age of 87 years. The average age was 32 years. More 
detailed comparative characteristics of the study population are shown in Table 
2. These results have been published previously [106]. 
Table 2: Characteristics of the study population groups (from [106]) 
  n Female 
n (%) 
Age in years 
mean (range) 
Inpatients Conservative 
wards 
87 38 (44%) 27 (1-100) 
Mixed specialities 45 45 (100%) 24 (16-39) 
Invasive wards 66 29 (44%) 40 (1-100) 
Health care 
workers 
Doctors 11 4 (36%) 50 (36-59) 
Nurses 75 52 (69%) 38 (19-57) 
Cleaning staff 11 11 (100%) 41 (27-49) 
General public Rural 102 57 (56%) 29 (1-81) 
Semi urban 103 47 (46%) 29 (1-90) 
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3.2 S. aureus carriage 
From all 500 participants we found 146 to be carriers of S. aureus. The carriage 
rate differed only slightly between the three major groups, giving a total carriage 
rate of 29%. 53 (27%) inpatients, 60 (29%) of the general public, and 33 (34%) 
health care workers were carriers [p>0.05]). 
For the general public there was a significant association between S. aureus 
carriage and living in the rural areas around Lambaréné. Subjects from rural 
areas had twice the risk of S. aureus carriage when compared to those from the 
semi-urban area of Lambaréné (OR = 2.2; 95% CI = 1.2–4.1; p = 0.01). For 
inpatients a significant increase of S. aureus carriage was found if they were 
staying in invasive or mixed wards. Table 3 displays more details of S. aureus’ 
prevalence and risk factors for carriage. These results have been published 
previously [106]. 
 
 
 
Table 3: Risk factors for S. aureus carriage (from [106]) 
  Carriers 
n (%) 
Odds Ratio 
(95% CI) 
p-value 
Gender Male 65 (30%) Ref - 
Female 81 (29%) 0.9 (0.6 - 1.4) 0.8 
Age in years <21 44 (28%) Ref - 
21-39 54 (32%) 1.2 (0.7 - 1.9) 0.4 
>39 48 (28%) 0.97 (0.5 - 1.5) 0.9 
Study group Population 60 (29%) Ref - 
Inpatients 53 (27%) 0.9 (0.6 - 1.4) 0.4 
Health care workers 33 (34%) 0.4 (0.7 - 2.1) 0.6 
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  Carriers 
n (%) 
Odds Ratio 
(95% CI) 
p-value 
General puplic Semi urban area 22 (21%) Ref - 
Rural area 38 (37%) 2.2 (1.2 - 4.1) 0.01 
Health care 
workers 
Doctors 6 (56%) Ref - 
Nurses 23 (31%) 0.5 (0.2 - 1.4) 0.2 
Cleaning staff 4 (36%) 1.1 (0.3 - 4.2) 0.8 
Inpatients Conservative wards 16 (18%) Ref - 
Mixed specialities 15 (33%) 2.4 (1.1 - 5.5) 0.03 
Invasive wards 22 (33%) 2.2 (1.1 - 4.6) 0.03 
 
 
3.3 Antimicrobial resistance 
 
 
Figure 2: Antimicrobial resistance (adapted from [106]) 
Among a total of 146 S. aureus isolates, 133 isolates were methicillin-
susceptible and resistant to penicillin (MSSA). All these strains were susceptible 
to cefoxitin or clindamycin, two strains were resistant to cotrimoxazol or 
n =8 n =5
n =133
Number (n) of S. aureus isolates
PSSA
MRSA
MSSA
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erythromycin (1.4%), respectively and one was resistant to chloramphenicol 
(0.7%). 
Among the 146 S. aureus isolates 5% (n = 8) were detected to be susceptible to 
penicillin (PSSA) and 3% (n = 5) were methicillin resistant and positive for mecA 
(MRSA). 
All the methicillin resistant isolates (MRSA; n = 5) were susceptible to 
rifampicin, vancomycin, teicoplanin, gentamicine, mupirocine, linezolid, 
fosfomycin and tigecycline. Three of the MRSA isolates were susceptible to 
cotrimoxazol and one MRSA isolate was intermediately susceptible to fusidic 
acid. 
These results have been published previously [106]. 
 
3.4 Virulence factors 
3.4.1 PVL and gamma-hemolysin 
All 146 isolates were positive for either pvl or hlg genes. 143 isolates (98%) 
were positive for hlg and 61 isolates (42%) were positive for pvl. To go into 
further detail, 58 isolates (40%) were positive for both genes, 85 isolates (58%) 
were positive for hlg only and 3 isolates (2%) for pvl only. 
 
3.4.2 Pyrogenic toxins 
Overall, 107 (73.0%) isolates were positive for at least one of the pyrogenic 
toxin superantigens (PTSAgs) tested. These comprise toxic shock syndrome 
toxin 1 (tst (9%)) and the staphylococcal enterotoxins (SEs: sea (35%), seb 
(10%), sec (13%), sed (1%), see (0%), seg (34%), seh (6%), sei (34%), sej 
(3%)). 
The most frequently found gene was the enterotoxin gene sea (n = 51; 35%), 
followed by seg and sei (n = 49; 34%). Seg and sei were always found in 
combination. Other PTSAgs were detected less frequently and gene see was 
not detected at all (Figure 3). 
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Figure 3: Distribution of pyrogenic toxin superantigens (PTSAgs) in % 
 
Combinations of different PTSAg genes were observed. The fixed combinations 
of seg plus sei was the most frequent combination found (34%; n = 49). In total, 
57 isolates (39%), possessed more than a single PTSAg gene - representing 
53% of all PTSAg gene-positive isolates, whereas 50 (34%) possessed only 
one PTSAg gene (Figure 4). Sea was the gene that was found most commonly 
sole (n = 39). 
 
 
Figure 4: Multiplicity of pyrogenic toxin superantigens (PTSAgs) 
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The combination of sed plus sej was found once (0.7%) in an isolate together 
with the additional PTSAg genes seb, seg and sei (ST5, t002).  
 
3.4.3 Exfoliative toxins, epidermal cell differentiation inhibitor and capsular 
polysaccharide types 5 and 8 
Ten of the S. aureus isolates (7%) harbored a gene encoding an exfoliative 
toxin. In Figure 5 the distribution can be seen. One isolate possessed eta and 
etb (ST 15, t326). 
Seven isolates possessed edin-B (5%) and one different isolate possessed 
edin-C (0.7 %) (ST 15, t326). Edin-A was not detected. 
Genes encoding for capsular polysaccharide type 8 (cap8) were detected in 
73% (n = 107) of the S. aureus isolates, whereas in only 25 % (n = 37) genes 
encoding for capsular polysaccharide type 5 (cap5) were detected. 2% (n = 2) 
did not harbor cap5 or cap8. 
 
 
Figure 5: Distribution of exfoliative toxin antigens (eta, etb,etd), of the genes encoding for 
members of the epidermal cell differentiation inhibitor (edin-A, edin-B, edin-C) and for capsular 
polysaccharide (cap5, cap8) 
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3.4.4 nuc gene, agr subtype 
One isolate showed no nuc gene expression (ST1822, t6331): its subsequent 
16S RNA gene sequencing confirmed clearly its specie’s affiliation to S. aureus 
[106]. 
Accessory gen regulator subtypes were distributed as follows among our S. 
aureus isolates: agr II was the most frequent subtype (n = 78; 53%) followed by 
agr I (n = 42; 29%), agr III (n= 16; 11%), and agr IV (n = 4; 3%), while two 
isolates did not harbor the agr subtypes I to IV (ST45, t939). Four isolates 
harbored two agr subtypes: agr I and agr II was co-detected in ST15 and ST188 
and agr II and agr III in ST1 and ST15 (Figure 6). These results have been 
published previously [106]. 
 
 
 
Figure 6: agr subtype distribution (from [106]) 
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3.5 Genotyping 
3.5.1 spa types 
Among a total of 146 S. aureus isolates, 53 different spa types were found. 
Most of the isolates belonged to spa type t084 (n = 50, 34%) followed by those 
belonging to t355 (n = 9, 6%), t148 (n = 7, 5%), t279 (n = 6, 4%), t1510 (n = 6, 
4%), t127 (n = 5, 3%), t1045 (n = 5, 3%), t311 (n = 3, 2%), and t2723 (n = 3, 
2%).  
Using the BURP algorithm spa clusters were formed and grouped into spa-
clonal complexes [106] resulting in spa-CC084 (n = 66), spa-CC304 (n = 7), 
spa-CC1045 (n = 7),and spa-CC1510 (n = 10). Thirteen spa types were 
singletons (n = 27), seven clusters had no founder (n = 27) and two spa types 
were excluded in the spa-clonal complexe grouping (n = 2) (t1113, t2980). 
These results have been published previously [106]. 
 
Sequence types (STs) 
Using MLST, 21 different STs were revealed among our 146 S. aureus isolates. 
ST15 (n = 69; 47%) was the most prevalent followed by ST508 (n = 12; 8%) 
and ST152 (n = 9; 6%). Three STs were described for the first time in this 
population designated ST1745, ST1746, and ST1822. ST1745 and ST1746 
were recovered from health care workers and ST1822 was recovered from a 
member of the general public. 
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Figure 7: Number of S. aureus isolates per sequence type (ST) (from [106]) 
 
 
Ten clonal complexes (CC) assigned by MLST could be found among the 146 
S. aureus isolates (Table 4). CC15 was the most frequent clonal complex, being 
detected 79 times. The other frequencies are shown in Table 4 as well as other 
characteristics of the complexes and their respective isolates. 
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MRSA isolates 
 
A detailed comparative characterization of the MRSA isolates and their 
genotyping results are shown in Table 5. 
 
SCCmec type: 
Out of the five mecA positive isolates, two (40%) harbored the SCCmec type IV 
(ST5, t653 and ST8, t121). The others were non SCCmec I to IV (here referred 
to as “not typeable”).These results have been published previously [106]. 
 
Table 5: Clinical characteristics and genotypes of the 5 MRSA isolates (adapted from [106]) 
ST = sequence type, PVL =Panton-Valentine leukocidin 
 
ST spa-CC spa 
type 
SCC 
mec 
type 
PVL agr 
type 
Addi 
tional 
virulence 
factors 
Study 
group 
Gender Age 
in 
year
s 
ST88 cluster5, 
no 
founder 
t186 nt negative III hlg, cap8 inpatient male 14 
ST88 cluster5, 
no 
founder 
t186 nt negative III sec, hlg, 
cap8 
health 
care 
worker 
female 38 
ST88 cluster5, 
no 
founder 
t729 nt negative III hlg, cap8 general 
puplic 
female 11 
ST8 304 t121 IV positive I hlg, cap5 inpatient male 31 
ST5 singleton t653 IV negative II seg, sei, 
sej, hlg, 
cap5 
health 
care 
worker 
male 49 
3 Results 
34 
3.5.2 Virulence factors in MRSA isolates 
3.5.2.1 PVL and gamma-hemolysin 
One of the five mecA positive isolates (20%) possessed the PVL-encoding 
genes lukF-PV and lukS-PV (ST8, t121) [106]. All 5 isolates were positive for 
the hlg gene. 
3.5.2.2 Pyrogenic toxins 
Two of the 5 isolates (40%) were positive for at least one of the pyrogenic toxin 
superantigens (PTSAgs) tested. One isolate was positive for sec (ST88, t186) 
and one positive for seg, sei and sej (ST5, t653). No isolate was positive for 
sea, seb, sed, see, she and tst.  
3.5.2.3 Exfoliative toxins and epidermal cell differentiation inhibitor 
No MRSA isolate harbored a gene encoding an exfoliative toxin and no MRSA 
isolate harbored edin-B, edin-A and edin-C.  
3.5.2.4 Capsular polysaccharide types 5 and 8 
Genes encoding for capsular polysaccharide type 8 were detected in three of 
the MRSA isolates (60%) whereas in two MRSA isolates (40%) genes encoding 
for capsular polysaccharide type 5 were detected [106]. 
3.5.2.5 agr subtype 
Agr III subtype was detected in three isolates (60%) and both agr I only and agr 
II only in one isolate (20%), respectively [106]. 
 
3.5.3 Genotying of MRSA isolates: spa types and sequence types 
The five MRSA had four different spa types. Two isolates belonged to the spa 
type t186 and one isolate to t121, t653 and t729 respectively. They clustered 
into different spa-CCs (spa-CC 5, spa-CC 304 and one isolate is a singleton). 
The MRSA isolates belonged to different lineages (ST5 (n = 1), ST8 (n = 1), and 
ST88 (n = 3)). These results have been published previously [106].. 
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4 Discussion 
S. aureus infections and MRSA have become major public health problems 
worldwide. To obtain a better understanding of the population structure of S. 
aureus, we document the population structure of 146 S. aureus isolates from 
asymptomatic carriers in Gabon. 
Among our study population a S. aureus carriage rate of about 29% was 
observed [106]. This prevalence is comparable to carriage rates reported in 
numerous studies worldwide ranging from 12% to 30% for persistent carriers of 
S. aureus [4].  
Among our study population a MRSA carriage rate of 1% was observed [106]. 
This prevalence is as well comparable to carriage rates reported in numerous 
studies worldwide ranging from less than 1% to 24% for MRSA carriage [102, 
103]. Notably, prevalences of MRSA carriage in Africa are reported to be higher 
ranging from 1.4% to 50% [104]. 
This study was not designed to reveal any possible difference betweenS. 
aureus carriage patterns in Gabon and those in other countries. In 
consequence, the sample taken for this study only allowed for inclusion of 
participants, depending on their momentary positive or negative sample results 
into either the group of carriers or noncarriers. As a result, intermittent carriers 
may be included in either one of the groups.  
The discussion will focus on the population structure of S. aureus isolates. 
Carriage rate and antimicrobial resistance of nearly the same study population 
is discussed in more detail in another doctorial thesis and article [105, 106]. 
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4.1 Virulence factors 
4.1.1 PVL and gamma-hemolysin 
In this study we a found high rate of PVL-positive (42%) S. aureus isolates. 
Similar or even higher rates for PVL-positive isolates have been found in other 
studies conducted in Gabon [150, 151] and other African countries such as 
Nigeria, Cameroon, Madagascar, Morocco, Niger, and Senegal [162, 107]. 
Comparably, Schaumburg et al. [150] showed a rate of 41% in isolates from 
persons asymptomatic for S. aureus related disease in Gabon. In their study 
[150] they could even show a significant association of PVL and S. aureus 
related infections by detecting a rate for PVL of 57% in this special group. 
In the United States, PVL-positive S. aureus used to be rare, but as was 
demonstrated by a study of 1,055 S. aureus infection isolates [108], its 
frequency of occurrence has increased nearly threefold during the years 2004 
through 2006 and was found at a rate of 40% in 2008.To go into further detail, 
in 2008, 12% of the MSSA strains and as much as 54% of the MRSA strains 
produced PVL, whereat 84% all PVL-producing isolates belonged to the so 
called “USA300” clone [108]. 
Interestingly, the prevalence of PVL in Europe is only 2% in MSSA in several 
studies [109, 95], whereas Monecke et al. described 30% PVL positive MSSA 
isolates in a study conducted in a German hospital [110]. In his study Monecke 
et al.analyzed isolates from diverse cases of skin and soft tissue 
infections.Contrarily, in our present study conducted in Gabon, only isolates 
from persons asymptomatic for S. aureus related disease were included.As 
PVL-producing S. aureus isolates have been linked in epidemiological studies 
to be more pathogenic, causing deep abscesses, severe necrotizing 
pneumonia, and severe bone and joint infections [51, 55] Monecke et al.´s 
result for the prevalence of PVL cannot be used for comparison with our study. 
PVL is usually associated with community-acquired S. aureus [111, 112] and 
with skin and soft tissue infection [152, 51]. As the PVL genes are carried on 
mobile genetic elements (prophages), genes may be transferred from one strain 
to another via phage transduction. PVL genes may thus be transmitted both 
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vertically within the same clones or horizontally among different clones either 
before or after acquisition of the mecA gene [113]. 
The clinical relevance of PVL in human infections is controversial. However, a 
large meta-analysis and pathophysiological studies provide evidence of its 
clinical relevance [152, 153, 154]. 
Almost all isolates were positive for gamma-hemolysin (98%). This is consistent 
with other studies [95]. 
 
4.1.2 Pyrogenic toxins 
Pyrogenic exotoxin genes are common in S. aureus, and are divergingly 
distributed among the different clonal types. As it is described elsewhere [97, 
114] up to 73% of S. aureus isolates carry at least one of these genes. 
Most of the pyrogenic exotoxin genes were observed less frequently in this 
study than in studies involving carrier isolates conducted in Europe [97, 155] 
and the United States [114]: tst (9% vs.22 - 78%), sec (13% vs. 14 - 27%), sed 
(1% vs. 3 - 23%), seg (34% vs. 57 - 90%), seh (6% vs. 6 - 15%), sei (34% vs. 
57 - 89%) and sej (3% vs. 3 - 9%). 
The prevalence of sea, seb and see were in the range of the prevalence 
described in these studies: sea (35% vs 14 - 58%), seb (10% vs 8 - 26%), see 
(0% vs 0 – 0.5%). Similar to the result of Becker et al. [97], in the present study 
we found that the possession of more than a single PTSAg gene was more 
frequent than the possession of only a single gene. In concurrence with Becker 
et al. [97], the combination that was found most often was the fixed 
combinations of seg plus sei. According to Zhang et al. [115], the enterotoxins 
sed and sej are located on the same plasmid linked by an intergenic region. 
However, in this study there were three S. aureus isolates that showed only sej 
genes. Morandi et al. [116] described a disconnection of sed plus sej. Unlike in 
our study, they found three isolates with sed genes only. 
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4.1.3 Exfoliative toxins and epidermal cell differentiation inhibitor 
The prevalence of genes encoding for exfoliative toxins was comparable to the 
prevalence of these genes found in Europe: eta (4% vs. 2 – 4%) [97,117], etb 
(0.7% vs. 1%) [97] and etd (3% vs. 5%) [118]. 
It is known that, the gene encoding edin-B is located on the chromosome within 
a pathogenicity island and genes encoding edin-A and edin-C are carried on 
plasmids [119]. The prevalence of these genes in this study was also 
comparable to the prevalence of these genes found in Europe: edin-A (0% vs. 
0%) [120], edin-B (5% vs.4 - 6%) [118, 120] and edin-C (0,7% vs. 0%) [120]. It 
should be noted, that the prevalence of edin-encoding genes is higher in clinical 
S. aureus isolates compared to that in S. aureus isolates from healthy carriers 
[120, 119]. In most studies on carrier or clinical isolates the predominant isoform 
found is edin-B. Interestingly, Munro et al. [119] reported a high prevalence of 
edin-C encoding toxin in clinical S. aureus isolates in France: 90% of all edin-
carrying S. aureus isolates carried the edin-C encoding toxin. They concluded 
that edin-C-positive isolates were more frequently associated with deep-seated 
soft tissue infections than other types of infections. Nevertheless, the 
association of certain S. aureus infections with edin production is still to be 
explored more extensively. 
 
4.1.4 Capsular polysaccharide types 5 and 8 
International epidemiological studies have shown that isolates of S. aureus are 
usually capsulated with either type 5 (~25%) or type 8 (~50%) capsular 
polysaccharides (CPs) [121] deriving from both carrier isolates and clinical 
isolates. Similarly, in this study serotype 5 and 8 account for 25% and 73% 
respectively. 
CP 5 and CP 8 have been reported to enhance virulence in a number of animal 
models of staphylococcal infection [122,123]. More precisely, Watts et al. [123] 
showed in a mouse model, that serotype 5 is more virulent than serotype 8. 
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Some authors see an option to use the major capsular polysaccharides type 5, 
type 8, and type 336 [124] as a target antigen for a vaccine to prevent S. aureus 
infections [121,125]. 
 
4.1.5 agr subtype 
Certain agr subtypes are distributed according to international epidemiological 
studies in a manner broadly consistent with our study results: agr I (29% vs. 30 
– 44%) and agr IV (3% vs. 0 - 6%) [117, 95, 126, 99]. However, agr II occurred 
more frequently (53% vs. 24 - 30%), whereas agr III occurred less frequently 
(11% vs. 25 - 34%) [117, 95, 126, 99]. 
Jarraud et al. [127] reported that the majority of exfoliative toxins-producing 
strains belong to agr IV. In contrast, all our exfoliative toxins-producing strains 
belonged to subtype I and II. 
In this study four isolates harbored two agr-subtypes. This is uncommon and 
could possibly be explained by a nonspecific primer binding in the multiplex 
PCR used here [106].  
As Jarraud et al. concluded “... though we cannot attribute a direct responsibility 
of the agr type in disease initiation, we can speculate that the preferential 
association between certain agr alleles, certain toxin genes, and a particular 
genetic background may make the activation of virulence factors more efficient 
…” [60]. 
 
 
4.2 Genotyping 
In this study, the major human lineages were identified, namely clonal 
complexes CC5, CC8, CC9, CC15, CC25, CC30 and CC45 [132]. 
The 21 STs of theS. aureus carriers were distributed unevenly. ST15 (mainly 
spa type t084) was found to be predominant (47%). Similarly, ST15 was the 
predominant sequence type in Malian carrier isolates (27%) [134], was found in 
other African countries (Algeria, Nigeria, South Africa, Cape Verde 
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Islands(11%) [107] or Ghana (18%) [156]) and it is commonly recorded as a 
major MSSA clone in countries in Asia (9%) [157], America and Europe (18%) 
[158]. 
The other 20 STs we found in Gabon were distributed more evenly, with the 
most frequent ST accounting for 9%. Most of them have been recognized as 
internationally well-disseminated clones including ST1, ST5, ST8, ST25, ST30, 
ST45, ST120 and ST121 [128, 132]. 
The prevalence of ST508 in other African countries was lower when compared 
to this study. Among carriers a prevalence of 1% was found in Mali [134], 
among clinical isolates a prevalence of 2.6% was found in Nigeria [104]. ST508 
associated with MRSA is described by Boyle-Vavra et al. [135]. In our study all 
S. aureus isolates of ST508 were positive of the fixed combination of seg plus 
sei. Three of the twelve ST508 isolats were additionally positive for sec and tst. 
ST1 is a pandemic MSSA clone and, as has been demonstrated in this study, it 
can be either PVL-negative or positive [104]. ST1 is also found to be a MRSA 
clone that has been highly associated with MRSA outbreaks in the United 
States (USA400 strains: PVL-positive ST1 SCCmec IV) and it very frequently 
has been associated with skin and soft tissue infections [129]. 
Our PVL-positive MSSA isolates were classified in clonal complexes CC15, 
CC121, CC88, CC5 and CC152. This is partly consistent with other studies from 
all continents. Especially PVL-producing MSSA belonging to CC121 is present 
in different countries around the world including Africa (Nigeria, Togo, South 
Africa) [162]. It should be noted, as Breurec et al. pointed out, that the two 
genetic backgrounds CC121 and CC15 (which was found predominatly in our 
study, mainly ST15) may not present a genetically steady environment for 
SCCmec integration as they have never (CC121) or rarely (CC15) been 
identified in MRSA isolates [107]. 
PVL-positive MSSA ST152 however is commonly found in West Africa. It was 
the predominant clone in North-Eastern Nigeria [140] and the second most 
prevalent clone in Mali [134]. To date, ST152 seems to be mainly present in 
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West Africa [162], whereas it has also been reported that ST152 was linked to a 
CA-MRSA genetic background in some countries in Europe [140, 107]. 
 
4.3 MRSA 
The MRSA isolates of this study carrying the methicillin resistance determinant 
mecA belonged to CC88 (n = 3, 60%), CC8 (n = 1, 20%), and CC5 (n = 1, 
20%). These clonal complexes are reported to be commonly present among 
MRSA strains worldwide [159]. CC8 and CC5 are widespread in Europe, the 
Americas, and Asia [133]. MRSA clones belonging to CC8 are known to be 
either hospital-acquired or community-associated [133]. Community-associated 
MRSA (CA-MRSA) are MRSA that developed separately from the hospital 
MRSA clones. Contrary to hospital-acquired MRSA strains, CA-MRSA strains 
usually carry lukS-PV and lukF-PV and SCCmec types IV and V [111, 112]. CA-
MRSA strains are known to be more virulent than HA-MRSA strains and they 
have begun to replace HA-MRSA in healthcare settings [111, 138]. Notably, 
ST8 is one of the most prevalent PVL-producing CA-MRSA clones in the United 
States [104]. More precisely, USA300 (named according to its PFGE pattern) is 
the predominant cause of infection in North America [53]. In Germany, USA300 
is less widely disseminated than in the United States but its proportion among 
all MRSA is steadily increasing since the last decade [53, 160]. 
Characteristically, USA300 exhibits MLST ST8, has spa type t008, produces 
PVL, and carries SCCmec types IV and the arginine catabolic mobile element 
(ACME) [28, 136, 137]. For our MRSA clone having ST8 we did not do a PFGE 
profile but it was also found to produces PVL and to carry SCCmec types IV but 
it was found to belong to the spa type t121. The spa type t121 (repeat pattern: 
11-19-21-17-34-24-34-22-25) is a single locus variant of t008 (repeat pattern: 
11-19-12-21-17-34-24-34-22-25). Isolates belonging to spa type t121 were also 
ACME-positive can therefore be considered to be closely related to the USA300 
clone although we did not perform PFGE. 
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ST5 is described to be a frequent MRSA clone worldwide, including in 
Africa,and is mostly associated with HA-MRSA infections [133, 145]. ST5 
isolates with all four SCCmec types have been identified, but types I and II are 
most prevalent [139]. Our ST5–MRSA possessed type IV, as does the so-called 
Pediatric clone [141]. The Pediatric clone, a health-care associated MRSA 
clone, was first described in a pediatric hospital in Portugal in 1992 and 
subsequently in different countries on several continents [142]. The “classic” 
Pediatric clone goes along with agr II and cap5 [143]. Our ST5-MRSA-IV 
matches these characteristics but it has a different and rarely reported spa type 
(t653) [161] and it does not produce PVL. However, this clone was detected 
from a physician, who had been working in the pediatric ward for several years 
aboth in Gabon as well as in various other countries. 
 
ST88, which was the major MRSA clone in this study, is well disseminated in 
Africa [107, 104, 145]. Beyond Africa, this clone seems to be rare but it has 
been isolated sporadically in Asia [144] and in Europe [145]. All our three ST88 
clones were non-SCCmec I through IV, carried agr III and did not produce PVL. 
Two clones were spa type t186. This is the same spa type Breurec et al. 
reported in a multicenter study to be the most frequent spa type present in 
Africa [145]. One of the isolates was obtained from a nurse working on a 
surgical ward and the other isolate was obtained from a young male who was a 
patient on this surgical ward. The other spa type t729 was also reported by 
Breurec et al. [145]. ST88 clones were also found in a great number in Nigeria, 
with the notable difference being the production of PVL by Nigerian clones 
[104]. ST88 has been described both in community and hospital settings [145]. 
 
In contrast to Van Leeuwen et al.[146], who found the agr I to be the most 
prevalent agr group in MRSA isolates, in our study agr III was the most frequent 
group. 
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In accordance with Ghebremedhin el at.[104], our MRSA strains were less 
“toxigenic” than the MSSA strains according to the tested virulence factors. 
More MSSA isolates harbored superantigenic toxin genes than did MRSA 
isolates. It should be noted that this differs from the results of a Japanese study 
[147]. That study, however, examined both clinical MSSA and MRSA isolates. 
 
Successful MRSA clones are usually associated with specific geographical 
areas. The factors underlying this observed fact are still being discussed. As 
Otter et al. summarize, important factors are most likely socioeconomic factors 
(such as hygienic habits and travel habits), antimicrobial prescribing policies 
and community/hospital outbreaks [53]. For instance, neither the main 
European CA-MRSA clone, ST80, nor one of the main MRSA clones found in 
Asia, ST30 [104], were detected in this study. 
 
 
4.4 Limitations of this work 
The main limitation of this work is the small number of MRSA observed in our 
study. The small number makes comparisons of MRSA characteristics difficult. 
Furthermore, the study was designed to only includeS. aureus from 
asymptomatic carriers and no clinical isolates were included. 
 
 
4.5 Conclusion 
This dissertation analyzes and reports on the population structure of S. aureus 
in Gabon. In doing so it provides some valuable information on S. aureus 
carriage and the molecular diversity of S. aureus not only within Gabon but also 
in comparison with other geographical regions.Most notably, we found, firstly, a 
high rate of PVL-positive S. aureus isolates and, secondly, more “toxigenic” 
MSSA isolates than MRSA isolates in terms of prevalence of superantigenic 
toxin genes. Thirdly, we found ST15 to be the predominant sequence type 
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represented in this study. Finally, the MRSA clone predominant in our study, 
ST88, is a MRSA clone that is widely distributed in Africa. 
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5 Summary 
 
Information about S. aureus in Africa is rare. This dissertation provides 
important information on both the S. aureus carriage rate and the S. aureus 
population structure in the Lambaréné area of Gabon. This cross-sectional 
study was conducted in 2009 in the semi-urban area of Lambaréné and its rural 
environment, in the Central African country of Gabon. Five hundred participants, 
all asymptomatic for S. aureus-related diseases were included in this study. 
Swabs were obtained from the anterior nares, the axilla, and the groin. 
Microbiological characterisation of the bacterial isolates was performed in the 
Microbiology Laboratory of the Centre de Recherches Médicales de 
Lambaréné, Gabon. Further analyses regarding molecular characterization 
were carried out at the Institute of Medical Microbiology, University of Münster 
(Germany). Some of the results have been published previously by Ateba-Ngoa 
et al. (2012). 
In this study 146 participants were found to be carrier of S.aureus. Among the 
146 S.aureus isolates five MRSA isolates were encountered. These 
prevalences are in accordance with the results of international studies. We 
found a high rate (42%) of PVL-producing S. aureus isolates. This is consistent 
with results from other African countries and the United States. In Europe, 
however, some studies show lower rates. PVL seems to contribute greatly to S. 
aureus’ virulence. In total, 73% of our S. aureus isolates carried at least one 
pyrogenic exotoxin gene. This is consistent with other studies. However, some 
of the genes were found less often in this study than in other studies with carrier 
isolates. The prevalence of genes encoding for exfoliative toxins and for 
epidermal cell differentiation inhibitor were comparable to the prevalence of 
these genes found in Europe. Compared to the MRSA isolates of this study, the 
MSSA isolates carried more superantigenic toxin genes. In accordance with 
other studies, 25% were capsulated with serotype 5 and 73% with serotype 8. 
In this study agr II occurred more frequently (53%) and agr III less frequently 
(11%) than elsewhere. Among the S. aureus isolates 46 different spa types 
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were represented, with 35% of isolates belonging to spa type t084. Among the 
isolates 21 different sequence types (ST) were represented with a clear 
predominance of ST15 (47%). In other African countries ST15 has also been 
reported to be the predominant sequence type. ST508 seems to be less 
frequent in other African countries than in this study. Most of the STs have 
already been reported as MRSA clones. Our MRSA clones, ST88, ST8, and 
ST5, are well disseminated worldwide. ST88, our predominant MRSA clone, is 
especially prevalent in Africa. We detected only one PVL-producing MRSA 
clone, a clone which is closely related to the hyperviulent clone “USA300”. 
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6 German summary 
 
Informationen über S. aureus in Afrika sind rar. Diese Doktorarbeit liefert 
wichtige Informationen sowohl über die Trägerrate von S. aureus als auch über 
die Populationstruktur von S. aureus im Gebiet um Lambaréné in Gabun. Diese 
Querschnittstudie wurde 2009 in der Stadt Lambaréné und ihrer ländlichen 
Umgebung durchgeführt. Lambaréné liegt in dem zentralafrikanischen Staat 
Gabun. In dieser Studie wurden 500 Teilnehmer aufgenommen, die alle 
asymptomatisch für S. aureus assoziierte Erkrankungen waren. Es wurden 
Abstriche vom Nasenvorhof, der Axilla und der Leiste genommen. Die 
mikrobiologischen Analysen der Bakterienisolate wurde im mikrobiologischen 
Labor der medizinischen Forschungseinheit des Albert Schweitzer 
Krankenhauses in Gabun durchgeführt. Weitere Analysen bezüglich 
molekularer Charakterisierung wurden am Institut für Mikrobiologie der 
Universität Münster in Deutschland ausgeführt. Einige der Resultate wurde 
bereits von Ateba-Ngoa et al. (2012) veröffentlicht. 
In dieser Studie waren 146 Teilnehmer Träger von S. aureus. Unter den 146 S. 
aureus Isolaten gab es fünf MRSA Isolate. Diese Prävalenzen entsprechen den 
Resultaten von internationalen Studien. Wir fanden eine hohe Rate (42%) von 
PVL-produzierenden S. aureus Isolaten. Dies stimmt mit Ergebnissen von 
anderen akfrikanischen Ländern und den Vereinigten Staaten überein. In 
Europa jedoch zeigen einige Studien niedrigere Raten. PVL scheint bedeutend 
zur Virulenz von S. aureus beizutragen. Insgesamt trugen 73% unserer S. 
aureus Isolate zumindest ein pyrogenes Exotoxingen. Dies stimmt mit anderen 
Studien überein. Einige der Gene jedoch wurden in dieser Studie weniger 
häufig gefunden als in anderen Studien mit Trägerisolaten. Die Prävalenz der 
Gene, welche für exfoliative Toxine und für den epidermalen 
Zelldifferenzierungs-inhibitor kodieren, war vergleichbar mit der Prävalenz 
dieser Gene in Europa. Im Vergleich zu den MRSA-Isolaten dieser Studie, 
trugen die MSSA-Isolate mehr Superantigene für Toxine. In Übereinstimmung 
mit anderen Studien waren 25% mit Serotyp 5 und 73% mit Serotyp 8 
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bekapselt. In dieser Studie kam agr II häufiger (53%) und agr III weniger häufig 
(11%) vor als anderwärts. Unter den S. aureus-Isolaten waren 46 verschiedene 
spa Typen repräsentiert, wobei 35% der Isolate zu spa type t084 gehörten. 
Unter den Isolaten waren 21 verschiedene Sequenztypen (ST) repräsentiert, 
mit eindeutigem Überwiegen von ST15 (47%). In anderen afrikanischen 
Ländern wurde ST15 ebenfalls als der prädominante Sequenztyp beschrieben. 
ST508 scheint in anderen afrikanischen Ländern seltener zu sein als in dieser 
Studie. Die meisten STs wurden bereits als MRSA-Klone beschrieben. Unsere 
MRSA-Klone, ST88, ST8 und ST5 sind auf der ganzen Welt weit verbreitet. 
Unser prädominanter MRSA-Klon ST88 ist vor allem in Afrika prävalent. Wir 
wiesen nur einen PVL produzierenden MRSA-Klon nach, welcher zu dem 
hypervirulenten Klon „USA300“ nahe verwandt ist. 
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